⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
PM360 Announces 2026 Lifetime Achievement Award Honoree, CMO of the Year, and Brand Champions
prnewswire.com
LLY
JNJ
BMY
MRK
REGN
KURA
BMRN
TAK
VRTX
GSK
AZN
AMGN
ABBV
Form 8-K
sec.gov
JNJ
Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
ACAD
BMY
JNJ
Surgical Devices Market Report 2026–2031 Now Available — Examines Capital Equipment and Ambulatory Surgery Centers
globenewswire.com
BSX
JNJ
STRL
ISRG
CNMD
TLF
Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight
globenewswire.com
CLRS
MDT
PHG
BSX
BDX
BIOT
ABT
ANGI
RMAX
MRK
SNY
JNJ
BA
GSK
AZN
PFE
NVO
AMGN
VRTX
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
prnewswire.com
JNJ
MRK
TEVA
LLY
ABBV
PFE
AZN
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
prnewswire.com
JNJ
EcoVadis and Novata Form New Partnership to Deliver High-Precision, Primary Carbon Data Integration for Corporate and Investor Decarbonization
prnewswire.com
JNJ
JPM
EcoVadis and Novata Form New Partnership to Deliver High-Precision, Primary Carbon Data Integration for Corporate and Investor Decarbonization
prnewswire.com
JNJ
JPM
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
businesswire.com
JNJ